Please login to the form below

Not currently logged in
Email:
Password:

AZ’s Gabriel Baertschi joins Grünenthal as CEO

He also becomes chairman of the corporate executive board

Grunenthal Gabriel BaertschiAachen, Germany-headquartered Grünenthal has named AstraZeneca's Gabriel Baertschi as its new chief executive officer, with effect from 1 October.

He succeeds Dr Eric-Paul Pâques who was appointed to the role in 2013, and retires at the end of the year.

Baertschi moves to the independent pharmaceutical firm from AstraZeneca, where he currently serves as country president for the company's operations in Japan.

Prior to taking up this role three years ago, Baertschi was AZ's country president for Germany and has led a number of its other operations in emerging markets.

Dr Wilhelm Moll, chairman of Grüenthal's supervisory board, said: “We are delighted that Gabriel Baertschi will join Grüenthal Group as chief executive officer.

“His deep experience in growing the business and developing the organisation in major developed and emerging markets will be a great asset for Grünenthal.

“He joins us at an exciting time when our strategy of expanding our strategic partnerships in research and development in Europe as well as in Latin America are accelerating our global growth.”

Dr Moll added: “We would like to thank Prof Dr Pâques for his outstanding leadership, integrity and extraordinary personal commitment for the future of a successful Grüenthal.”

15th June 2016

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

APAC map
Pharmaceutical innovation in the APAC region
A first-of-its-kind study paints a vivid picture of the APAC region’s future...
Patient journey mapping: exploring the clinical and the emotional journey
By Chris Hodgson, Neil Rees, Sumira Riaz and Karen Petticrew While we can all agree that the value of developing a patient journey map cannot be underestimated when exploring the...
Precision medicine at Blue Latitude Health
At Blue Latitude Health we have identified 90+ insights about commercialising precision medicines. Check out our video to get a run down on three core components of the commercialisation and...

Infographics